Table 3 EBV DNA loads in various EBV-associated disease states and immunocompromised individuals.
| Group | Patient ID | Sex/Age | Condition |
Specimen (Positive/n Tested) | Target | Detectable EBV DNA Load (copies/ml) | Clinical Notes |
|---|---|---|---|---|---|---|---|
| 1. | A. | M/46y | PTLD | Plasma (5/6) | EBNA-1 | Day +32 - 8.0 × 102 | MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected on Days +32, +39, +46, +60, +75 and +81 for EBV QPCR; Plasma EBV (qualitative) PCR positive on Days +75, +78 and +81; Treatment with Foscarnet and Rituximab after Day +75; Died of pneumonia on Day +88 |
| Day +46 - 1.0 × 103 | |||||||
| Day +60 - 8.8 × 103 | |||||||
| Day +75 - 1.1 × 106 | |||||||
| Day +81 - 2.3 × 105 | |||||||
| CSF (2/2) | EBNA-1 | Day +75 - 1.3 × 106 | CSF collected on Days +75 and +78 | ||||
| Day +78 - 2.7 × 106 | |||||||
| B. | M/42y | PTLD | Whole Blood (1/5) | EBNA-1 | Day +95 - 2.0 × 107 | MUD HSCT for AML; Plasma EBV (qualitative) PCR positive Day +96; Plasma collected on Day +95 for EBV QPCR; Died on Day +99 due to multi-organ failure | |
| C. | F/59y | PTLD | Plasma (3/6) | EBNA-1 | Day +45 - 2.2 × 105 | MUD HSCT for AML; CMV reactivation on Day +44, Treatment with Foscarnet and ganciclovir on Day +52; Plasma collected Days +38, +40, +45, +52 and +59; Died on Day +66; EBV VCA IgG positive, HHV6 IgG positive and CMV IgG positive pre-Tx | |
| Day +52 - 9.6 × 103 | |||||||
| Day +59 - 3.0 × 105 | |||||||
| Whole Blood (1/8) | EBNA-1 | Day +46 - 6.6 × 104 | EDTA collected Days +3, +5, +10, +17, +26, +31, +33, +46 | ||||
| D. | M/48y | PTLD | Plasma (4/6) | EBNA-1 | Day +40 - 3.4 × 103 | MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected Days +28, +33, +40, +47, +54, +61; Plasma EBV (qualitative) PCR negative on Day +62; Died Day +72 of multi-organ failure | |
| Day +47 - 3.6 × 104 | |||||||
| Day +54 - 3.4 × 106 | |||||||
| Day +61 - 6.3 × 106 | |||||||
| Whole Blood (2/2) | EBNA-1 | Day +62 - 1.3 × 108 | EDTA collected Days +62 and +63. | ||||
| Day +63 - 1.8 × 107 | |||||||
| E. | F/57y | PTLD | Whole Blood (1/5) | EBNA-1 | 9.5 × 104 | No serology results available however clinical notes indicate EBV reactivation; Plasma EBV (qualitative) PCR positive 9-16 days after VL testing done; negative at 1-7 months thereafter. | |
| 2. | F. | Unknown | IM | Plasma (1/1) | EBNA-1 | 3.7 × 104 | EBV VCA IgM positive |
| BHRF-1 | 1.6 × 104 | ||||||
| G. | Unknown | IM | Plasma (0/1) | EBNA-1 | 0 | EBV VCA IgM positive | |
| BHRF-1 | 0 | ||||||
| H. | Unknown | IM | Plasma (1/1) | EBNA-1 | 7.6 × 103 | EBV VCA IgM positive | |
| BHRF-1 | 1.5 × 103 | ||||||
| I. | Unknown | IM | Plasma (1/1) | EBNA-1 | 2.3 × 103 | EBV VCA IgM positive | |
| BHRF-1 | 8.7 × 104 | ||||||
| J. | M/17y | IM | Whole Blood (1/1) | EBNA-1 | 1.0 × 105 | EBV VCA IgM positive | |
| BHRF-1 | 1.8 × 103 | ||||||
| K. | F/19y | IM | Whole Blood (1/1) | EBNA-1 | 2.2 103 | EBV VCA IgM positive | |
| BHRF-1 | 5.6 × 104 | ||||||
| L. | F/53y | IM | Whole Blood (1/1) | EBNA-1 | 2.0 × 105 | EBV VCA IgM positive; acute glandular fever | |
| BHRF-1 | 1.8 × 104 | ||||||
| 3. | M. | M/36y | EBVAHS | Whole Blood (1/1) | EBNA-1 | 7.5 × 104 | EBV (qualitative) PCR positive; died of EBVAHS |
| BHRF-1 | 1.1 × 105 | ||||||
| 4. | N. | Unknown | HIV | Plasma (1/1) | EBNA-1 | 0 | HIV plasma VL 324, 000 RNA copies/ml |
| BHRF-1 | 1.0 × 103 | ||||||
| O. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 13, 000 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| P. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 26, 800 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| Q. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 21, 300 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| R. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 12, 700 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| S. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 1, 040, 000 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| T. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 17, 700 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| U. | Unknown | HIV | Plasma (0/1) | EBNA-1, | 0 | HIV plasma VL 47, 500 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| V. | Unknown | HIV | Plasma (1/1) | EBNA-1 | 5.6 × 103 | HIV plasma VL 16, 400 RNA copies/ml | |
| BHRF-1 | 3.0 × 103 | ||||||
| W. | Unknown | HIV | PBMC (1/1) | EBNA-1 | < 2.0 × 102 | HIV PBMC VL 12, 800 RNA copies/ml | |
| BHRF-1 | < 2.0 × 102 | ||||||
| X. | Unknown | HIV | PBMC (1/1) | EBNA-1 | < 2.0 × 102 | HIV PBMC VL 12, 700 RNA copies/ml | |
| BHRF-1 | 0 | ||||||
| Y. | Unknown | HIV | PBMC (0/1) | EBNA-1, | 0 | HIV PBMC VL 118, 000 RNA copies/ml | |
| BHRF-1 |